CA2290624C - Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs - Google Patents
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs Download PDFInfo
- Publication number
- CA2290624C CA2290624C CA002290624A CA2290624A CA2290624C CA 2290624 C CA2290624 C CA 2290624C CA 002290624 A CA002290624 A CA 002290624A CA 2290624 A CA2290624 A CA 2290624A CA 2290624 C CA2290624 C CA 2290624C
- Authority
- CA
- Canada
- Prior art keywords
- drug
- dosage form
- polymeric matrix
- weight
- immersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
Drugs that are freely or highly soluble in water are formulated as unit dosage forms by incorporating them into polymeric matrices comprised of high molecular weight hydrophilic polymers that swell upon imbibition of water. The dosage form can be a single compressed tablets, or two or three compressed tablets retained in a single gelatin capsule. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial erosion of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby limits the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric environment.
Description
GASTRIC-RETENTIVE ORAL DRUG
DOSAGE FORMS FOR CONTROLLED RELEASE
s OF HIGHLY SOLUBLE DRUGS
This invention is in the general field of pharmacology, and relates in particular to drug delivery systems that are retained in the stomach for an extended period of time while releasing a highly soluble drug in a controlled manner over an extended period of time, in order to achieve greater efficacy and more efficient use of the drug.
BACKGROUND OF THE INVENTION
The rate at which drugs that are administered in conventional tablets or capsules become available to body fluids is initially very high, followed by a rapid decline. For many drugs, this pattern results in a transient overdose, followed by a long period of underdosing. This is of limited clinical usefulness. The delivery pattern was improved in is the 1970's with the introduction of a variety of controlled delivery systems. By providing relatively constant, controlled drug delivery, these systems avoided the overdose and the underdose effects. These improvements provided effective medication with reduced side effects, and achieved these results with reduced dosing frequency.
Many of these controlled delivery systems utilize hydrophilic, polymeric matrices that provide useful levels of control to the delivery of sparingly soluble drugs. For soluble drugs, however, and particularly for highly soluble drugs, such matrices do not provide adequate control over the drug release rate, instead resulting in a release that approximates first-order kinetics. The rate of release is therefore an inverse function of the square root of the elapsed time. With first-order release kinetics, most of the drug in the matrix is 2s released within the first two hours in an aqueous medium.
One method of prolonging the release of a highly water-soluble drug is disclosed in International Patent Application Publication No. WO 96/26718 (Temple University; Kim, inventor). The method of this publication is the incorporation of the drug into a polymeric matrix to form a tablet that is administered orally. The polymer is water-swellable yet erodible in gastric juices, and the polymer and the proportion of drug to polymer are chosen such that:
(i) the rate at which the polymer swells is equal to the rate at which the polymer erodes, so that the swelling of the polymer is continuously held in check by the erosion, and zero-order release kinetics of the drug from the matrix are maintained;
(ii) the release of drug from the matrix is sustained over the full erosion period of the polymer, the tablet therefore reaching full solubilization at the same time that the last of the drug is released; and (iii) release of the drug from the matrix will be extended over a period of 24 hours.
A key disclosure in WO 96/26718 is that to achieve the release of drug in this manner requires the use of a low molecular weight polymer. If, by contrast, a high molecular weight polymer is used and the swelling rate substantially exceeds the erosion rate, the lack of erosion will prolong the diffusion of the drug residing close to the center of the tablet and prevent it from being released. Thus, there is no disclosure in WO 96/26718 that a drug of high water solubility can be released from a high molecular weight polymer in a period of time substantially less than 24 hours, or that any advantage can be obtained by the use of a polymer that does not erode as quickly as it swells. This failure is particularly significant since even swollen tablets will not remain in the stomach beyond the duration of the fed mode, which typically lasts for only 6 to 8 hours.
SUMMARY OF THE TNVENTION
It has now been discovered that drugs that are highly soluble in water can be administered orally in a manner that will prolong their delivery time to extend substantially through the duration of the fed mode but not a substantial time beyond. This is achieved by using a formulation in which the drug is dispersed in a polymeric matrix that is water-swellable rather than merely hydrophilic, and that erodes at a rate that is substantially less than its swelling rate. It has further been found that the diffusion rate can be slowed by increasing the drug particle size, by the choice of polymer used in the matrix, or by the molecular weight of the polymer. The matrix is a relatively high molecular weight polymer that swells upon ingestion to achieve a size that is at least about twice its unswelled volume and that promotes gastric retention during the fed mode. Upon swelling, the matrix also converts over a prolonged period of time from a glassy polymer to a polymer that is rubbery in consistency. The penetrating fluid then causes release of the drug in a gradual and prolonged manner by the process of solution diffusion, i. e. , dissolution of the drug in the penetrating fluid and diffusion of the dissolved drug back out of the matrix. The matrix itself is solid prior to administration and, once administered, remains undissolved in (i. e. , uneroded by} the gastric fluid for a period of time su~cient to permit the majority of the drug to be released by the solution diffusion process during the fed mode. The rate-limiting factor in the release of the drug is therefore controlled diffusion of the drug from the matrix rather than erosion, dissolution or chemical decomposition of the matrix.
The swelling of the polymeric matrix thus achieves two results -- (i) it swells the matrix to a size large enough to cause it to be retained in the stomach during the fed mode, and (ii) it retards the rate of diffusion of a highly soluble drug long enough to provide multi-hour, controller) delivery of the drug into the stomach. This combination of gastric retention and controlled delivery of soluble drugs provides an effective means of using these drugs to treat local stomach disorders. For example, use of this invention provides more effective eradication of an ulcer-causing bacterium in the gastric mucosa with soluble antibiotics. The invention also provides enhanced absorption of soluble drugs that are absorbed mostly in the stomach or high in the gastrointestinal tract, such as metformin hydrochloride or ciprofloxacin. The invention is also useful in providing a multi-hour flow of a drug past the upper part of the small intestine (the most efficient absorption site fox many agents).
3a In one aspect of the invention, there is provided a controlled-release oral drug dosage form for releasing a drug, one part by weight of the drug being capable of dissolving in less than ten parts by weight of water, the dosage form comprising a solid polymeric matrix in which the drug is dispersed at a weight ratio of drug to polymer of about 80:20 or less, the polymeric matrix being one that swells to at least about twice its volume upon imbibition of water, that releases the drug into gastric fluid by the dissolution and diffusion of the drug out of the matrix by the gastric fluid, that upon immersion in gastric fluid retains at least about 40%
of the drug one hour after such immersion and releases substantially all of the drug within about eight hours after such immersion, and that remains substantially intact until all of the drug is released.
In another aspect of the invention, there is provided a controlled-release oral drug dosage form for releasing a drug, one part by weight of said drug being capable of dissolving in less than ten parts by weight of water, said dosage form comprising a solid polymeric matrix in which said drug is dispersed at a weight ratio of drug to polymer of about 80:20 or less, said dosage form being one that swells to a size large enough to promote retention in the stomach during the fed mode, that releases said drug into gastric fluid by the dissolution and diffusion of said drug out of said matrix by said gastric fluid, that upon immersion in gastric fluid retains at least about 40% of said drug one hour after such immersion.
The one part by weight of said drug may be capable of dissolving in less than about five parts by weight of water or may be capable of dissolving in less than about three parts by weight of water. The drug may be metformin hydrochloride, vancomycin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, or ticlopidine hydrochloride.
The polymeric matrix may be formed of polyethylene oxide), xanthan gum, cellulose, alkyl-substituted celluloses, crosslinked polyacrylic acids, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose. The polymeric matrix may be formed of polyethylene oxide) at a molecular weight of at least about 4,500,000, a molecular weight in the range of about 4,500,000 to about 10,000,000, or a molecular weight in the range of about 5,000,000 to about 8,000,000. The weight ratio of drug to polymer may be from about 15:85 to about 80:20, from about 30:70 to about 80:20, or from about 30:70 to about 70:30. The polymeric matrix upon immersion in gastric fluid may retain at least about 50%, 60% or 80% of the drug one hour after such immersion. The dosage form may further comprise a hydrophobic additive 3b formulated with the drug to further retard the release of the drug to the gastric fluid. The polymeric matrix may consist of two cylindrical tablets, each measuring about 9mm to about 12 mm in length and about 6.5 mm to about 7 mm in diameter. The polymeric matrix may consist of a single elongated tablet measuring about 18 mm to about 22 mm in length, about 6.5 mm to about 7.8 mm in width, and about 6.2 to 7.5 mm in height.
Details of these and other features of the invention will be apparent from the description that follows.
FIG. 1 is a plot showing the release rate of metformin hydrochloride from three different compositions of the drug in polyethylene oxide) matrices.
FIG. 2 is a plot showing the release rate of captopril from a polyethylene oxide) matrix, in accordance with this invention, both with and without glyceryl monostearate as a solubility modifier.
FIG. 3 is a plot showing the release rate of captopril from hydroxyethyl cellulose, in which the pellet size was varied.
FIG. 4 is a plot showing the release rate of metformin hydrochloride from various polymeric matrices.
FIG. 5 is a plot showing the release rate of metformin hydrochloride from a single capsule-shaped pellet.
FIG. 6 is a plot showing the release rate of captopril from various polymeric matrices.
FIG. 7 is a plot showing further release rate studies of metformin hydrochloride from two different polymeric matrices.
FIG. 8 is a plot showing the release rate of vancomycin hydrochloride from different polymeric matrices.
DETAILED DESCRIPTION OF THE INVENTION
AND PREFERRED EMBODIMENTS
Drugs to which the present invention applies are those that are characterized by the United States Pharmacopeia XXII as at least "freely soluble" in water, i. e. , one part of the drug dissolves in less than about ten parts of water. Drugs of particular interest are those that require only about five parts of water or less (per one part of drug) to dissolve, and drugs of even greater interest are those that require only about three parts of water or less.
The parts referred to in this paragraph are parts by weight.
The term "drug" is used herein to denote any chemical compound, complex or composition that is suitable for oral administration and that has a beneficial biological effect, preferably a therapeutic effect in the treatment of a disease or abnormal physiological condition. Examples of drugs to which this invention is applicable are metformin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, and ticlopidine hydrochloride. Other drugs suitable for use and meeting the solubility parameters described above will be apparent to those skilled in the art. Drugs of particular interest are metformin hydrochloride and sertraline hydrochloride.
The drug loadings (weight percent of drug relative to total of drug and polymer) in most of these cases will be about 80% or less.
The invention is also of use with drugs that have been formulated to include additives that impart a small degree of hydrophobic character, to further retard the release rate of the drug into the gastric fluid. One example of such a release rate retardant is glyceryl monostearate. Other examples are fatty acids and salts of fatty acids, one example of which is sodium myristate. The quantities of these additives when present can vary; and in most cases, the weight ratio of additive to drug will range from about 1:10 to about 2:1, and preferably from about 1: 8 to about 1: 2.
The water-swellable polymer forming the matrix in accordance with this invention is any polymer that is non-toxic, that swells in a dimensionally unrestricted manner upon imbibition of water, and that provides for sustained release of an incorporated drug.
Polymers having molecular weights of about 4,500,000 and higher are preferred.
More preferred are polymers with molecular weights within the range of about 4,500,000 to about 10,000,000, and even more preferred are polymers with molecular weights within the range of about 5,000,000 to about 8,000,000. In many cases, polymers are more commonly characterized in terms of the viscosity of polymer solutions at a given concentration and temperature. Preferred viscosity ranges for various classes of polymers are given below. Examples of polymers suitable for use in this invention are cellulose 5 polymers and their derivatives, polysaccharides and their derivatives, polyalkylene oxides, and crosslinked polyacrylic acids and their derivatives.
The term "cellulose" is used herein to denote a linear polymer of anhydroglucose.
Preferred cellulose polymers are alkyl-substituted cellulose polymers that ultimately dissolve in the gastrointestinal (G.I.) tract in a predictably delayed manner.
Preferred alkyl-substituted cellulose derivatives are those substituted with alkyl groups of 1 to 3 carbon atoms each. Examples are methylcellulose, hydroxymethylcellulose, hydroxyethyl-cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethyl-cellulose. In terms of their viscosities, one class of preferred alkyl-substituted celluloses includes those whose viscosity is within the range of about 100 to about 110,000 centipoise as a 2% aqueous solution at 20°C. Another class includes those whose viscosity is within the range of about 1,000 to about 4,000 centipoise as a 1 % aqueous solution at 20°C.
Particularly preferred alkyl-substituted celluloses are hydroxyethylcellulose and hydroxy-propylmethylcellulose. A presently preferred hydroxyethylcellulose is NATRASOL~
250HX NF (National Formulary), available from Aqualon Company, Wilmington, Delaware, USA.
Polyalkylene oxides of greatest utility in this invention are those having the properties described above for alkyl-substituted cellulose polymers. A
particularly preferred polyalkylene oxide is polyethylene oxide), which term is used herein to denote a linear polymer of unsubstituted ethylene oxide. Preferred polyethylene oxides are those with a weight-average molecular weight within the range of about 9 x 105 to about 8 x 106. Polyethylene oxides are often characterized by their viscosity in solution. For purposes of this invention, a preferred viscosity range is about 50 to about 2,000,000 centipoise for a 2% aqueous solution at 20°C. Two presently preferred polyethylene oxides are POLYOX~ NF, grade WSR Coagulant, molecular weight 5 million, and grade WSR 303, molecular weight 7 million, both products of Union Carbide Chemicals and Plastics Company Inc. of Danbury, Connecticut, USA.
Polysaccharide gums, both natural and modified (semi-synthetic) can be used.
Examples are dextran, xanthan gum, gellan gum, welan gum and rhamsan gum.
Xanthan gum is preferred.
Crosslinked polyacrylic acids of greatest utility are those whose properties are the same as those described above for alkyl-substituted cellulose and polyalkylene oxide polymers. Preferred crosslinked polyacrylic acids are those with a viscosity ranging from about 4,000 to about 40,000 centipoise for a 1 % aqueous solution at 25 °C. Three presently preferred examples are CARBOPOL~ NF grades 971P, 974P and 934P
(BFGoodrich Co., Specialty Polymers and Chemicals Div., Cleveland, Ohio, USA).
Further examples are polymers known as WATER LOCK~, which are starch/acrylates/-acrylamide copolymers available from Grain Processing Corporation, Muscatine, Iowa, USA.
The hydrophilicity and water swellability of these polymers cause the drug-containing matrices to swell in size in the gastric cavity due to ingress of water in order to achieve a size that will be retained in the stomach when introduced during the fed mode.
These qualities also cause the matrices to become slippery, which provides resistance to peristalsis and further promotes their retention in the stomach. The release rate of a drug from the matrix is primarily dependent upon the rate of water imbibition and the rate at which the drug dissolves and diffuses from the swollen polymer, which in turn is related to the solubility and dissolution rate of the drug, the drug particle size and the drug concentration in the matrix. Also, because these polymers dissolve very slowly in gastric fluid, the matrix maintains its integrity over at least a substantial period of time, in many cases at least 90 % and preferably over 100 % of the dosing period. The particles will then slowly dissolve or decompose. In most cases, complete dissolution or decomposition will occur within 8 to 10 hours after the intended dosing period.
The amount of polymer relative to the drug can vary, depending on the drug release rate desired and on the polymer, its molecular weight, and excipients that may be present in the formulation. The amount of polymer will be sufficient however to retain at least about 40% of the drug within the matrix one hour after ingestion (or immersion in the gastric fluid). Preferably, the amount of polymer is such that at least 50% of the drug remains in the matrix one hour after ingestion. More preferably, at least 60 %
, and most preferably at least 80 % , of the drug remains in the matrix one hour after ingestion. In all cases, however, the drug will be substantially all released from the matrix within about eight hours after ingestion, and the polymeric matrix will remain substantially intact until all of the drug is released. The term "substantially intact" is used herein to denote a polymeric matrix in which the polymer portion substantially retains its size and shape without deterioration due to becoming solubilized in the gastric fluid or due to breakage into fragments or small particles.
The water-swellable polymers can be used individually or in combination.
Certain combinations will often provide a more controlled release of the drug than their components when used individually. Examples are cellulose-based polymers combined with gums, such as hydroxyethyl cellulose or hydroxypropyl cellulose combined with xanthan gum. Another example is polyethylene oxide} combined with xanthan gum.
The benefits of this invention will be achieved at drug loadings of about 80%
or less (l. e. , the weight percent of drug relative to total of drug and polymer), with preferred loadings within the range of 15 % to 80 % , more preferably within the range of 30 % to 80 % , and most preferably in certain cases within the range of about 30 % to 70 % .
The formulations of this invention may assume the form of particles, tablets, or particles retained in capsules. A preferred formulation consists of particles consolidated into a packed mass for ingestion, even though the packed mass will separate into individual particles after ingestion. Conventional methods can be used for consolidating the particles in this manner. For example, the particles can be placed in gelatin capsules known in the art as "hard-filled" capsules and "soft-elastic" capsules. The compositions of these capsules and procedures for filling them are known among those skilled in drug formulations and manufacture. The encapsulating material should be highly soluble so that the particles are freed and rapidly dispersed in the stomach after the capsule is ingested.
One presently preferred dosage form is a size 0 gelatin capsule containing either two or three pellets of drug-impregnated polymer. For two-pellet capsules, the pellets are cylindrically shaped, 6.6 or 6.7 mm (or more generally, 6.5 to 7 mm) in diameter and 9.5 or 10.25 mm (or more generally, 9 to 12 mm) in length. For three-pellet capsules, the pellets are again cylindrically shaped, 6.6 mm in diameter and 7 mm in length.
For a size 00 gelatin capsule with two pellets, the pellets are cylindrical, 7.5 mm in diameter and 11.25 mm in length. For a size 00 gelatin capsule with three pellets, the pellets are cylindrical, 7.5 mm in diameter and 7.5 mm in length. Another presently preferred dosage form is a single, elongated tablet, with dimensions 18 to 22 mm in length, 6.5 to 7.8 mm in width, and 6.2 to 7.5 mm in height. A preferred set of dimensions is 20 mm in length, 6.7 mm in width, and 6.4 mm in height. These are merely examples;
the shapes and sizes can be varied considerably.
The particulate drug/polymer mixture or drug-impregnated polymer matrix can be prepared by various conventional mixing, comminution and fabrication techniques readily apparent to those skilled in the chemistry of drug formulations. Examples of such techniques are as follows:
(1) Direct compression, using appropriate punches and dies, such as those available from Elizabeth Carbide Die Company, Inc., McKeesport, Pennsylvania, USA; the punches and dies are fitted to a suitable rotary tableting press, such as the Elizabeth-Hata single-sided Hata Auto Press machine, with either 15, 18 or 22 stations, and available from Elizabeth-Hata International, Inc., North Huntington, Pennsylvania, USA; and (2) Injection or compression molding using suitable molds fitted to a compression unit, such as those available from Cincinnati Milacron, Plastics Machinery Division, Batavia, Ohio, USA.
When particles are made by direct compression, the addition of lubricants may be helpful and sometimes important to promote powder flow and to prevent capping of the particle (breaking off of a portion of the particle) when the pressure is relieved. Useful lubricants are magnesium stearate (in a concentration of from 0.25 % to 3 % by weight, preferably less than 1 % by weight, in the powder mix), and hydrogenated vegetable oil (preferably hydrogenated and refined triglycerides of stearic and palmitic acids at about S 1 % to 5 % by weight, most preferably about 2 % by weight. Additional excipients may be added to enhance powder flowability and reduce adherence.
The term "dosage form" denotes any form of the formulation that contains an amount sufficient to achieve a therapeutic effect with a single administration. When the formulation is a tablet or capsule, the dosage form is usually one such tablet or capsule.
The frequency of administration that will provide the most effective results in an efficient manner without overdosing will vary with the characteristics of the particular drug, including both its pharmacological characteristics and its physical characteristics such as solubility, and with the characteristics of the swellable matrix such as its permeability, and the relative amounts of the drug and polymer. In most cases, the dosage form will be such that effective results will be achieved with administration no more frequently than once every eight hours or more, preferably once every twelve hours or more, and even more preferably once every twenty-four hours or more.
As indicated above, the dosage forms of the present invention find their greatest utility when administered to a subject who is in the digestive or "fed" mode.
During this mode, particulate matter above a certain minimum particle size is retained in the subject's stomach. The fed mode is distinguished from the fasting mode, which prevails during nighttime rest and into the early morning hours. The fasting mode is characterized by interdigestive migrating motor complex (MMC) waves, which are intense contractions beginning midway down the stomach and continuing down the intestinal tract to the distal ileum, clearing the stomach of digested materials as well as indigestible solids within a certain size range that would be retained if the stomach were in the fed mode.
The fed mode is initiated by the ingestion of food, and causes suspension of the MMC
waves, thereby permitting the stomach to retain the particulate matter long enough to be broken down and at least partially digested. When the fed mode passes, the MMC waves of the fasting mode resume.
The fed mode can be initiated by a signal triggered by the ingestion of food, or by a chemical signal based on nutrient and osmotic factors, which can be supplied with the ingestion of food or administered specifically to initiate the fed mode. These factors include hypertonic solutions, acid, fat, certain carbohydrates, and certain amino acids. Fat is the most powerful of these factors, relaxing the fundus with lower intragastric pressure, increasing the reservoir function of the proximal stomach, contracting the pyloric sphincter, and changing intestinal peristalsis from a propagated series of waves to segmenting activity.
The following examples are offered for purposes of illustration, and are not intended to limit the invention in any manner.
This example illustrates the controlled-release behavior of metformin hydrochloride, a highly soluble drug (whose solubility is approximately 35 %), from a polymeric matrix consisting of polyethylene oxide). Three different dose levels were prepared --systems designed to release 90 % of their drug contents at approximately 3 hours, 6 hours, and 8 hours, respectively.
Drug and polymer, with 0.5 % magnesium stearate as a tableting lubricant, were compressed into pellets measuring 7.2 mm diameter x 8.8 mm length and weighing 390 mg for samples designed for 3-hour and 6-hour release, and 7.4 mm diameter x 8.5 mm length and weighing 380 mg for samples designed for 8-hour release, and two pellets of a given type were incorporated into a single gelatin capsule. Thus, three different types of gelatin capsule were prepared as follows:
t~% - 3 hours:
metformin hydrochloride 250.00 mg POLYOX~ 1105, molecular weight 900,000 138.67 magnesium stearate 1.95 Totai: 390.62 mg t~% = 6 hours:
metformin hydrochloride 250.00 mg POLYOX~ Coagulant, molecular weight 5,000,000 138.67 magnesium stearate 1.95 Total: 390.62 mg t~% = 8 hours:
metformin hydrochloride 125.00 mg POLYOX~ 303, molecular weight 7,000,000 266.11 magnesium stearate 1.97 Total: 393.08 mg Release rate tests on each of these three formulations were performed in modified artificial gastric fluid by the following procedure.
Dissolution was performed in a USP Apparatus 2, modified to include a stainless steel cone (7/8 inch in height and 7/8 inch in diameter at the base) at the bottom of each 5 vessel, placed directly beneath the paddle shaft to eliminate the "dead zone" effect. A
paddle speed of 60 rpm and a bath temperature of 37.4°C were used. , The gelatin capsule was opened and the individual pellets and empty gelatin capsule were dropped into the dissolution vessel containing 900 mL of modified simulated gastric fluid (7 mL
of hydrochloric acid and 2 g of sodium chloride in 100 mL of deionized water; the enzyme 10 pepsin was omitted). Once the pellets had settled to the bottom of the vessel, the paddle rotation was initiated. Samples 5 mL in size were taken at specified time points, and the sample volumes were not replaced. The samples were diluted as necessary for quantitative analysis by HPLC.
The results are shown in FIG. 1, where the filled diamonds represent the t~%
__ 3 formulation, the x's represent the t~~ - 6 formulation, and the open circles represent the t~% = 8 formulation. The curves show that the t~~ value of the first formulation was fairly close to 3.5 hours, the t~% value of the second formulation was fairly close to 6.0 hours, and t~% value of the third formulation was fairly close to 7.5 hours.
This example illustrates the controlled-release behavior of captopril from a polymeric matrix consisting of polyethylene oxide), both with and without glyceryl monostearate (8% by weight). The formulations used were as follows:
1. Captopril 925.0 mg Polyethylene oxide) (POLYOX~ 301), molecular weight 4,000,000 4,075.0 Total 5,000.00 mg 2. Captopril 925.0 mg glyceryl monostearate 150.0 Polyethylene oxide) (POLYOX~ 301), molecular weight 4,000,000 3.925.0 Total 5,000.0 mg Each formulation was compressed into a tablet measuring 6.0 mm diameter x 6.7 mm length and weighing 180 mg. Release rate tests on each of the two tablets were performed in modified simulated gastric fluid by the procedure of Example 1, except that the paddle rotation speed was 30 rpm and the tablets were dropped directly into the dissolution vessel.
S The results are shown in FIG. 2, where the filled squares represent Formulation No. 1 consisting of captopril and polyethylene oxide) only, and the open circles represent Formulation No. 2 which further contained glyceryl monostearate.
This example illustrates the controlled-release behavior of captopril from a polymeric matrix of hydroxyethyl cellulose with the inclusion of glyceryl monostearate, but at varying pellet sizes. The formulation contained 19% captopril (all percents by weight) and 4. 8 % glyceryl monostearate in hydroxyethyl cellulose of molecular weight within the range of 1,000,000 to 1,500,000. The pellet sizes and weights were (a) 3.3 mm diameter x 3.S mm length at 3S mg (referred to herein as 3-mm tablets), (b) 4.3 nun 1S diameter x 4.9 mm length at 7S mg (referred to herein as 4-mm tablets), and (c) 6.3 mm diameter x 6.S mm length at 187 mg (referred to herein as 6-mm tablets).
Release rate tests on each of the three tablet sizes (fifteen of the 3-mm tablets, seven of the 4-mm tablets, and three of the 6-mm tablets) were performed using the procedures of Example 1, except that a weighted watchglass was used in place of the stainless steel cone, and analyses of the samples were performed by UV/Vis.
The results are shown in FIG. 3, where the filled squares represent the 3-mm pellets, the filled triangles the 4-mm pellets, and the filled circles the 6-mm pellets. This demonstrates the variation of pellet size as a further means of varying the release pattern, the larger pellets having less surface area.
This example further illustrates the controlled release of metformin hydrochloride, using a higher drug loading, and various polymers and combinations of polymers. The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 4 where the results are plotted, were as follows (all percentages are by weight):
Filled circles: 79.6% metformin HCI; 20% polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000); 0.4% magnesium stearate. Pellet dimensions 6.04 mm diameter x 9.48 mm length; containing approximately 478 mg metformin HCI.
Filled squares: 79.6% metformin HCI; 20% xanthan gum (KELTROL~ F, Kelco, Div.
of Merck & Co., Inc., San Diego, California, USA); 0.4% magnesium stearate.
Pellet dimensions 6.06 mm diameter x 9.40 mm length; containing approximately 483 mg metformin HCI.
Plus signs: 79.6% metformin HCI; 20% hydroxypropylmethyl cellulose (BENECEL~
824, Aqualon Co., Wilmington, Delaware, USA), viscosity (2%, 20°C) 11,000 to 15,000 cps; 0.4% magnesium stearate. Pellet dimensions 6.06 mm diameter x 9.49 mm length; containing approximately 480 mg metformin HCI.
Open diamonds: 79.6 % metformin HCI; 5 % hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 15% polyethylene oxide (POLYOX~ 303, molecular weight 7,000,000); 0.4% magnesium stearate. Pellet dimensions 6.06 mm diameter x 9.60 mm length; containing approximately 480 mg metformin HCI.
x's: 79.6% metformin HCI, 18.05% xanthan gum (KELTROL~ F); 1.99% WATER
LOCK~ D-223 (starch graft poly(2-propenamide-co-2-propenoic acid)), mixed sodium and aluminum salts, Grain Processing Corporation, Muscatine, Iowa, USA); 0.4 % magnesium stearate. Pellet dimensions were 6.06 mm diameter x 9.24 mm length; containing approximately 476 mg metformin HCI total.
This example further illustrates the controlled release of metformin hydrochloride from a single capsule-shaped tablet. The procedures used were the same as those described above, and the resulting curve is plotted in FIG. 5. The formulation was as follows (all percentages are by weight): 64 % metformin HCI; 35.5 %
polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000); 0.5 % magnesium stearate; plus an additional 2 % OPADRY~ Clear coating (hydroxypropyl methylcellulose, Colorcon, West Point, Pennsylvania, USA). The tablet dimensions were 6.48 mm diameter x 7.20 mm height x 19.21 mm length, and contained approximately 506 mg metformin HCl per tablet.
This example further illustrates the controlled release of captopril, using various polymers and combinations of polymers. The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 6 where the results are plotted, were as follows (all percentages are by weight):
Plus signs: 80 % captopril; 20 % hydroxypropylmethyl cellulose (BENECEL~ 824, viscosity (2%, 20°C) 11,000 to 15,000 cps). Pellet dimensions: 6.03 mm diameter x 9.25 mm length, 2 pellets weighing 293 mg each, containing approximately 468.6 mg captopril total.
Filled diamonds: 80% captopril; 20% xanthan gum (KELTROL~ F}. Pellet dimensions:
6.04 mm diameter x 9.18 mm length, 2 pellets weighing 299 mg each, containing approximately 477.8 mg captopril total.
Filled triangles: 80% captopril; 20% hydroxyethyl cellulose (250HX, molecular weight 1,000,000}. Pellet dimensions: 6.03 mm diameter x 9.53 mm length, 2 pellets weighing 299 mg each, containing approximately 478.2 mg captopril total.
Open circles: 80% captopril; 20% polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000). Pellet dimensions: 6.04 mm diameter x 9.59 mm length, 2 pellets weighing 301 mg each, containing approximately 481.6 mg captopril total.
Filled squares: 80% captopril; 20% carboxymethyl cellulose (12M31P, molecular weight 250,000). Pellet dimensions: 6.04 mm diameter x 9.18 mm length, 2 pellets weighing 299 mg each, containing approximately 477.6 mg captopril total.
Open triangles: 79.93 % captopril; 10.03 % hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 10.04% xanthan gum (KELTROL~ F). Pellet dimensions:
6.04 mm diameter x 9.26 mm length, 2 pellets weighing 296 mg each, containing approximately 478.2 mg captopril total.
x's: 79.96% captopril; 10.03% hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 10.01 % polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000). Pellet dimensions: 6.04 mm diameter x 9.41 mm length, 2 pellets weighing 297 mg each, containing approximately 483 mg captopril total.
Dashes: 80 % captopril; 10 % hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 10% hydroxypropylmethyl cellulose (BENECEL~ 824, viscosity (2%, 20°C) 11,000 to 15,000 cps). Pellet dimensions: 6.04 mm diameter x 9.41 mm length, 2 pellets weighing 298 mg each, containing approximately 476.6 mg captopril total.
Open diamonds: 79.96 % captopril; 18.05 % xanthan gum (KELTROL~ F); 1.99 WATERLOCK~ D-223. Pellet dimensions: 6.04 mm diameter x 9.16 mm length, 2 pellets weighing 297 mg each, containing approximately 475 mg captopril total.
This example presents further data on metformin hydrochloride formulations, illustrating the effect of lower drug loadings than those used in the preceding examples.
The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 7 where the results are plotted, were as follows (all percentages are by weight):
Filled squares: 32.5% metformin HCI; 67% polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000); 0.5 % magnesium stearate. Pellet dimensions 6.62 mm diameter x 10.40 mm length, 2 pellets weighing 400 mg each, containing approximately 260 mg metformin HCl total.
Open circles: 32.5 % metformin HCI; 67 % xanthan gum (KELTROL~ F); 0.5 magnesium stearate. Pellet dimensions 6.65 mm diameter x 9.28 mm length; 2 pellets weighing 401 mg each, containing approximately 261 mg metformin HCl total.
This example illustrates the sustained release of vancomycin hydrochloride from various polymers. The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 8 where the results are plotted, were as follows (all percentages are by weight):
Open squares: 31.5 % vancomycin hydrochloride; 68 % polyethylene oxide) (POLYOX
303, molecular weight 7,000,000); 0.5 % magnesium stearate. Pellet dimensions:
6.59 mm diameter x 10.23 mm length, 2 pellets weighing 403 mg each, containing approximately 253 mg vancomycin hydrochloride total.
5 Open triangles: 31.5 % vancomycin hydrochloride; 68 % polyethylene oxide) (POLYOX m 301, molecular weight 4,000,000); 0.5% magnesium stearate. Pellet dimensions:
6.59 mm diameter x 10.28 mm length, 2 pellets weighing 402 mg each, containing approximately 253 mg vancomycin hydrochloride total.
x's: 31.5% vancomycin hydrochloride; 68% hydroxypropyl methylcellulose (BENECEL~
10 824, viscosity 11,000-15,000 cps (2% solution at 20°C)); 0.5%
magnesium stearate. Pellet dimensions: 6.59 mm diameter x 10.10 mm length, 2 pellets weighing 405 mg each, containing approximately 255 mg vancomycin hydrochloride total.
Open circles: 31.5% vancomycin hydrochloride; 68% xanthan gum (KELTROL~ F);
15 0.5 % magnesium stearate. Pellet dimensions: 6.62 mm diameter x 9.77 mm length, 2 pellets weighing 401 mg each, containing approximately 253 mg vancomycin hydrochloride total.
Filled squares: 62.5 % vancomycin hydrochloride; 37 % polyethylene oxide) (POLYOX
303, molecular weight 7,000,000); 0.5 % magnesium stearate. Pellet dimensions:
6.60 mm diameter x 10.01 rnm length, 2 pellets weighing 409 mg each, containing approximately 508 mg vancomycin hydrochloride total.
In the prior art, vancomycin and its salts are administered by injection, due to poor absorption when administered orally. By providing for all or at least a portion of the total administered amount to be delivered by controlled delivery in the gastric retentive system of this invention, that portion so delivered is directed to the proximal portion of the small intestine, the most efficient site for absorption of this drug, resulting in an enhanced absorption from the oral dosage form of the invention.
The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the components, additives, proportions, methods of formulation, and other parameters of the invention can be modified further or substituted in various ways without departing from the spirit and scope of the invention.
DOSAGE FORMS FOR CONTROLLED RELEASE
s OF HIGHLY SOLUBLE DRUGS
This invention is in the general field of pharmacology, and relates in particular to drug delivery systems that are retained in the stomach for an extended period of time while releasing a highly soluble drug in a controlled manner over an extended period of time, in order to achieve greater efficacy and more efficient use of the drug.
BACKGROUND OF THE INVENTION
The rate at which drugs that are administered in conventional tablets or capsules become available to body fluids is initially very high, followed by a rapid decline. For many drugs, this pattern results in a transient overdose, followed by a long period of underdosing. This is of limited clinical usefulness. The delivery pattern was improved in is the 1970's with the introduction of a variety of controlled delivery systems. By providing relatively constant, controlled drug delivery, these systems avoided the overdose and the underdose effects. These improvements provided effective medication with reduced side effects, and achieved these results with reduced dosing frequency.
Many of these controlled delivery systems utilize hydrophilic, polymeric matrices that provide useful levels of control to the delivery of sparingly soluble drugs. For soluble drugs, however, and particularly for highly soluble drugs, such matrices do not provide adequate control over the drug release rate, instead resulting in a release that approximates first-order kinetics. The rate of release is therefore an inverse function of the square root of the elapsed time. With first-order release kinetics, most of the drug in the matrix is 2s released within the first two hours in an aqueous medium.
One method of prolonging the release of a highly water-soluble drug is disclosed in International Patent Application Publication No. WO 96/26718 (Temple University; Kim, inventor). The method of this publication is the incorporation of the drug into a polymeric matrix to form a tablet that is administered orally. The polymer is water-swellable yet erodible in gastric juices, and the polymer and the proportion of drug to polymer are chosen such that:
(i) the rate at which the polymer swells is equal to the rate at which the polymer erodes, so that the swelling of the polymer is continuously held in check by the erosion, and zero-order release kinetics of the drug from the matrix are maintained;
(ii) the release of drug from the matrix is sustained over the full erosion period of the polymer, the tablet therefore reaching full solubilization at the same time that the last of the drug is released; and (iii) release of the drug from the matrix will be extended over a period of 24 hours.
A key disclosure in WO 96/26718 is that to achieve the release of drug in this manner requires the use of a low molecular weight polymer. If, by contrast, a high molecular weight polymer is used and the swelling rate substantially exceeds the erosion rate, the lack of erosion will prolong the diffusion of the drug residing close to the center of the tablet and prevent it from being released. Thus, there is no disclosure in WO 96/26718 that a drug of high water solubility can be released from a high molecular weight polymer in a period of time substantially less than 24 hours, or that any advantage can be obtained by the use of a polymer that does not erode as quickly as it swells. This failure is particularly significant since even swollen tablets will not remain in the stomach beyond the duration of the fed mode, which typically lasts for only 6 to 8 hours.
SUMMARY OF THE TNVENTION
It has now been discovered that drugs that are highly soluble in water can be administered orally in a manner that will prolong their delivery time to extend substantially through the duration of the fed mode but not a substantial time beyond. This is achieved by using a formulation in which the drug is dispersed in a polymeric matrix that is water-swellable rather than merely hydrophilic, and that erodes at a rate that is substantially less than its swelling rate. It has further been found that the diffusion rate can be slowed by increasing the drug particle size, by the choice of polymer used in the matrix, or by the molecular weight of the polymer. The matrix is a relatively high molecular weight polymer that swells upon ingestion to achieve a size that is at least about twice its unswelled volume and that promotes gastric retention during the fed mode. Upon swelling, the matrix also converts over a prolonged period of time from a glassy polymer to a polymer that is rubbery in consistency. The penetrating fluid then causes release of the drug in a gradual and prolonged manner by the process of solution diffusion, i. e. , dissolution of the drug in the penetrating fluid and diffusion of the dissolved drug back out of the matrix. The matrix itself is solid prior to administration and, once administered, remains undissolved in (i. e. , uneroded by} the gastric fluid for a period of time su~cient to permit the majority of the drug to be released by the solution diffusion process during the fed mode. The rate-limiting factor in the release of the drug is therefore controlled diffusion of the drug from the matrix rather than erosion, dissolution or chemical decomposition of the matrix.
The swelling of the polymeric matrix thus achieves two results -- (i) it swells the matrix to a size large enough to cause it to be retained in the stomach during the fed mode, and (ii) it retards the rate of diffusion of a highly soluble drug long enough to provide multi-hour, controller) delivery of the drug into the stomach. This combination of gastric retention and controlled delivery of soluble drugs provides an effective means of using these drugs to treat local stomach disorders. For example, use of this invention provides more effective eradication of an ulcer-causing bacterium in the gastric mucosa with soluble antibiotics. The invention also provides enhanced absorption of soluble drugs that are absorbed mostly in the stomach or high in the gastrointestinal tract, such as metformin hydrochloride or ciprofloxacin. The invention is also useful in providing a multi-hour flow of a drug past the upper part of the small intestine (the most efficient absorption site fox many agents).
3a In one aspect of the invention, there is provided a controlled-release oral drug dosage form for releasing a drug, one part by weight of the drug being capable of dissolving in less than ten parts by weight of water, the dosage form comprising a solid polymeric matrix in which the drug is dispersed at a weight ratio of drug to polymer of about 80:20 or less, the polymeric matrix being one that swells to at least about twice its volume upon imbibition of water, that releases the drug into gastric fluid by the dissolution and diffusion of the drug out of the matrix by the gastric fluid, that upon immersion in gastric fluid retains at least about 40%
of the drug one hour after such immersion and releases substantially all of the drug within about eight hours after such immersion, and that remains substantially intact until all of the drug is released.
In another aspect of the invention, there is provided a controlled-release oral drug dosage form for releasing a drug, one part by weight of said drug being capable of dissolving in less than ten parts by weight of water, said dosage form comprising a solid polymeric matrix in which said drug is dispersed at a weight ratio of drug to polymer of about 80:20 or less, said dosage form being one that swells to a size large enough to promote retention in the stomach during the fed mode, that releases said drug into gastric fluid by the dissolution and diffusion of said drug out of said matrix by said gastric fluid, that upon immersion in gastric fluid retains at least about 40% of said drug one hour after such immersion.
The one part by weight of said drug may be capable of dissolving in less than about five parts by weight of water or may be capable of dissolving in less than about three parts by weight of water. The drug may be metformin hydrochloride, vancomycin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, or ticlopidine hydrochloride.
The polymeric matrix may be formed of polyethylene oxide), xanthan gum, cellulose, alkyl-substituted celluloses, crosslinked polyacrylic acids, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose. The polymeric matrix may be formed of polyethylene oxide) at a molecular weight of at least about 4,500,000, a molecular weight in the range of about 4,500,000 to about 10,000,000, or a molecular weight in the range of about 5,000,000 to about 8,000,000. The weight ratio of drug to polymer may be from about 15:85 to about 80:20, from about 30:70 to about 80:20, or from about 30:70 to about 70:30. The polymeric matrix upon immersion in gastric fluid may retain at least about 50%, 60% or 80% of the drug one hour after such immersion. The dosage form may further comprise a hydrophobic additive 3b formulated with the drug to further retard the release of the drug to the gastric fluid. The polymeric matrix may consist of two cylindrical tablets, each measuring about 9mm to about 12 mm in length and about 6.5 mm to about 7 mm in diameter. The polymeric matrix may consist of a single elongated tablet measuring about 18 mm to about 22 mm in length, about 6.5 mm to about 7.8 mm in width, and about 6.2 to 7.5 mm in height.
Details of these and other features of the invention will be apparent from the description that follows.
FIG. 1 is a plot showing the release rate of metformin hydrochloride from three different compositions of the drug in polyethylene oxide) matrices.
FIG. 2 is a plot showing the release rate of captopril from a polyethylene oxide) matrix, in accordance with this invention, both with and without glyceryl monostearate as a solubility modifier.
FIG. 3 is a plot showing the release rate of captopril from hydroxyethyl cellulose, in which the pellet size was varied.
FIG. 4 is a plot showing the release rate of metformin hydrochloride from various polymeric matrices.
FIG. 5 is a plot showing the release rate of metformin hydrochloride from a single capsule-shaped pellet.
FIG. 6 is a plot showing the release rate of captopril from various polymeric matrices.
FIG. 7 is a plot showing further release rate studies of metformin hydrochloride from two different polymeric matrices.
FIG. 8 is a plot showing the release rate of vancomycin hydrochloride from different polymeric matrices.
DETAILED DESCRIPTION OF THE INVENTION
AND PREFERRED EMBODIMENTS
Drugs to which the present invention applies are those that are characterized by the United States Pharmacopeia XXII as at least "freely soluble" in water, i. e. , one part of the drug dissolves in less than about ten parts of water. Drugs of particular interest are those that require only about five parts of water or less (per one part of drug) to dissolve, and drugs of even greater interest are those that require only about three parts of water or less.
The parts referred to in this paragraph are parts by weight.
The term "drug" is used herein to denote any chemical compound, complex or composition that is suitable for oral administration and that has a beneficial biological effect, preferably a therapeutic effect in the treatment of a disease or abnormal physiological condition. Examples of drugs to which this invention is applicable are metformin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, and ticlopidine hydrochloride. Other drugs suitable for use and meeting the solubility parameters described above will be apparent to those skilled in the art. Drugs of particular interest are metformin hydrochloride and sertraline hydrochloride.
The drug loadings (weight percent of drug relative to total of drug and polymer) in most of these cases will be about 80% or less.
The invention is also of use with drugs that have been formulated to include additives that impart a small degree of hydrophobic character, to further retard the release rate of the drug into the gastric fluid. One example of such a release rate retardant is glyceryl monostearate. Other examples are fatty acids and salts of fatty acids, one example of which is sodium myristate. The quantities of these additives when present can vary; and in most cases, the weight ratio of additive to drug will range from about 1:10 to about 2:1, and preferably from about 1: 8 to about 1: 2.
The water-swellable polymer forming the matrix in accordance with this invention is any polymer that is non-toxic, that swells in a dimensionally unrestricted manner upon imbibition of water, and that provides for sustained release of an incorporated drug.
Polymers having molecular weights of about 4,500,000 and higher are preferred.
More preferred are polymers with molecular weights within the range of about 4,500,000 to about 10,000,000, and even more preferred are polymers with molecular weights within the range of about 5,000,000 to about 8,000,000. In many cases, polymers are more commonly characterized in terms of the viscosity of polymer solutions at a given concentration and temperature. Preferred viscosity ranges for various classes of polymers are given below. Examples of polymers suitable for use in this invention are cellulose 5 polymers and their derivatives, polysaccharides and their derivatives, polyalkylene oxides, and crosslinked polyacrylic acids and their derivatives.
The term "cellulose" is used herein to denote a linear polymer of anhydroglucose.
Preferred cellulose polymers are alkyl-substituted cellulose polymers that ultimately dissolve in the gastrointestinal (G.I.) tract in a predictably delayed manner.
Preferred alkyl-substituted cellulose derivatives are those substituted with alkyl groups of 1 to 3 carbon atoms each. Examples are methylcellulose, hydroxymethylcellulose, hydroxyethyl-cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethyl-cellulose. In terms of their viscosities, one class of preferred alkyl-substituted celluloses includes those whose viscosity is within the range of about 100 to about 110,000 centipoise as a 2% aqueous solution at 20°C. Another class includes those whose viscosity is within the range of about 1,000 to about 4,000 centipoise as a 1 % aqueous solution at 20°C.
Particularly preferred alkyl-substituted celluloses are hydroxyethylcellulose and hydroxy-propylmethylcellulose. A presently preferred hydroxyethylcellulose is NATRASOL~
250HX NF (National Formulary), available from Aqualon Company, Wilmington, Delaware, USA.
Polyalkylene oxides of greatest utility in this invention are those having the properties described above for alkyl-substituted cellulose polymers. A
particularly preferred polyalkylene oxide is polyethylene oxide), which term is used herein to denote a linear polymer of unsubstituted ethylene oxide. Preferred polyethylene oxides are those with a weight-average molecular weight within the range of about 9 x 105 to about 8 x 106. Polyethylene oxides are often characterized by their viscosity in solution. For purposes of this invention, a preferred viscosity range is about 50 to about 2,000,000 centipoise for a 2% aqueous solution at 20°C. Two presently preferred polyethylene oxides are POLYOX~ NF, grade WSR Coagulant, molecular weight 5 million, and grade WSR 303, molecular weight 7 million, both products of Union Carbide Chemicals and Plastics Company Inc. of Danbury, Connecticut, USA.
Polysaccharide gums, both natural and modified (semi-synthetic) can be used.
Examples are dextran, xanthan gum, gellan gum, welan gum and rhamsan gum.
Xanthan gum is preferred.
Crosslinked polyacrylic acids of greatest utility are those whose properties are the same as those described above for alkyl-substituted cellulose and polyalkylene oxide polymers. Preferred crosslinked polyacrylic acids are those with a viscosity ranging from about 4,000 to about 40,000 centipoise for a 1 % aqueous solution at 25 °C. Three presently preferred examples are CARBOPOL~ NF grades 971P, 974P and 934P
(BFGoodrich Co., Specialty Polymers and Chemicals Div., Cleveland, Ohio, USA).
Further examples are polymers known as WATER LOCK~, which are starch/acrylates/-acrylamide copolymers available from Grain Processing Corporation, Muscatine, Iowa, USA.
The hydrophilicity and water swellability of these polymers cause the drug-containing matrices to swell in size in the gastric cavity due to ingress of water in order to achieve a size that will be retained in the stomach when introduced during the fed mode.
These qualities also cause the matrices to become slippery, which provides resistance to peristalsis and further promotes their retention in the stomach. The release rate of a drug from the matrix is primarily dependent upon the rate of water imbibition and the rate at which the drug dissolves and diffuses from the swollen polymer, which in turn is related to the solubility and dissolution rate of the drug, the drug particle size and the drug concentration in the matrix. Also, because these polymers dissolve very slowly in gastric fluid, the matrix maintains its integrity over at least a substantial period of time, in many cases at least 90 % and preferably over 100 % of the dosing period. The particles will then slowly dissolve or decompose. In most cases, complete dissolution or decomposition will occur within 8 to 10 hours after the intended dosing period.
The amount of polymer relative to the drug can vary, depending on the drug release rate desired and on the polymer, its molecular weight, and excipients that may be present in the formulation. The amount of polymer will be sufficient however to retain at least about 40% of the drug within the matrix one hour after ingestion (or immersion in the gastric fluid). Preferably, the amount of polymer is such that at least 50% of the drug remains in the matrix one hour after ingestion. More preferably, at least 60 %
, and most preferably at least 80 % , of the drug remains in the matrix one hour after ingestion. In all cases, however, the drug will be substantially all released from the matrix within about eight hours after ingestion, and the polymeric matrix will remain substantially intact until all of the drug is released. The term "substantially intact" is used herein to denote a polymeric matrix in which the polymer portion substantially retains its size and shape without deterioration due to becoming solubilized in the gastric fluid or due to breakage into fragments or small particles.
The water-swellable polymers can be used individually or in combination.
Certain combinations will often provide a more controlled release of the drug than their components when used individually. Examples are cellulose-based polymers combined with gums, such as hydroxyethyl cellulose or hydroxypropyl cellulose combined with xanthan gum. Another example is polyethylene oxide} combined with xanthan gum.
The benefits of this invention will be achieved at drug loadings of about 80%
or less (l. e. , the weight percent of drug relative to total of drug and polymer), with preferred loadings within the range of 15 % to 80 % , more preferably within the range of 30 % to 80 % , and most preferably in certain cases within the range of about 30 % to 70 % .
The formulations of this invention may assume the form of particles, tablets, or particles retained in capsules. A preferred formulation consists of particles consolidated into a packed mass for ingestion, even though the packed mass will separate into individual particles after ingestion. Conventional methods can be used for consolidating the particles in this manner. For example, the particles can be placed in gelatin capsules known in the art as "hard-filled" capsules and "soft-elastic" capsules. The compositions of these capsules and procedures for filling them are known among those skilled in drug formulations and manufacture. The encapsulating material should be highly soluble so that the particles are freed and rapidly dispersed in the stomach after the capsule is ingested.
One presently preferred dosage form is a size 0 gelatin capsule containing either two or three pellets of drug-impregnated polymer. For two-pellet capsules, the pellets are cylindrically shaped, 6.6 or 6.7 mm (or more generally, 6.5 to 7 mm) in diameter and 9.5 or 10.25 mm (or more generally, 9 to 12 mm) in length. For three-pellet capsules, the pellets are again cylindrically shaped, 6.6 mm in diameter and 7 mm in length.
For a size 00 gelatin capsule with two pellets, the pellets are cylindrical, 7.5 mm in diameter and 11.25 mm in length. For a size 00 gelatin capsule with three pellets, the pellets are cylindrical, 7.5 mm in diameter and 7.5 mm in length. Another presently preferred dosage form is a single, elongated tablet, with dimensions 18 to 22 mm in length, 6.5 to 7.8 mm in width, and 6.2 to 7.5 mm in height. A preferred set of dimensions is 20 mm in length, 6.7 mm in width, and 6.4 mm in height. These are merely examples;
the shapes and sizes can be varied considerably.
The particulate drug/polymer mixture or drug-impregnated polymer matrix can be prepared by various conventional mixing, comminution and fabrication techniques readily apparent to those skilled in the chemistry of drug formulations. Examples of such techniques are as follows:
(1) Direct compression, using appropriate punches and dies, such as those available from Elizabeth Carbide Die Company, Inc., McKeesport, Pennsylvania, USA; the punches and dies are fitted to a suitable rotary tableting press, such as the Elizabeth-Hata single-sided Hata Auto Press machine, with either 15, 18 or 22 stations, and available from Elizabeth-Hata International, Inc., North Huntington, Pennsylvania, USA; and (2) Injection or compression molding using suitable molds fitted to a compression unit, such as those available from Cincinnati Milacron, Plastics Machinery Division, Batavia, Ohio, USA.
When particles are made by direct compression, the addition of lubricants may be helpful and sometimes important to promote powder flow and to prevent capping of the particle (breaking off of a portion of the particle) when the pressure is relieved. Useful lubricants are magnesium stearate (in a concentration of from 0.25 % to 3 % by weight, preferably less than 1 % by weight, in the powder mix), and hydrogenated vegetable oil (preferably hydrogenated and refined triglycerides of stearic and palmitic acids at about S 1 % to 5 % by weight, most preferably about 2 % by weight. Additional excipients may be added to enhance powder flowability and reduce adherence.
The term "dosage form" denotes any form of the formulation that contains an amount sufficient to achieve a therapeutic effect with a single administration. When the formulation is a tablet or capsule, the dosage form is usually one such tablet or capsule.
The frequency of administration that will provide the most effective results in an efficient manner without overdosing will vary with the characteristics of the particular drug, including both its pharmacological characteristics and its physical characteristics such as solubility, and with the characteristics of the swellable matrix such as its permeability, and the relative amounts of the drug and polymer. In most cases, the dosage form will be such that effective results will be achieved with administration no more frequently than once every eight hours or more, preferably once every twelve hours or more, and even more preferably once every twenty-four hours or more.
As indicated above, the dosage forms of the present invention find their greatest utility when administered to a subject who is in the digestive or "fed" mode.
During this mode, particulate matter above a certain minimum particle size is retained in the subject's stomach. The fed mode is distinguished from the fasting mode, which prevails during nighttime rest and into the early morning hours. The fasting mode is characterized by interdigestive migrating motor complex (MMC) waves, which are intense contractions beginning midway down the stomach and continuing down the intestinal tract to the distal ileum, clearing the stomach of digested materials as well as indigestible solids within a certain size range that would be retained if the stomach were in the fed mode.
The fed mode is initiated by the ingestion of food, and causes suspension of the MMC
waves, thereby permitting the stomach to retain the particulate matter long enough to be broken down and at least partially digested. When the fed mode passes, the MMC waves of the fasting mode resume.
The fed mode can be initiated by a signal triggered by the ingestion of food, or by a chemical signal based on nutrient and osmotic factors, which can be supplied with the ingestion of food or administered specifically to initiate the fed mode. These factors include hypertonic solutions, acid, fat, certain carbohydrates, and certain amino acids. Fat is the most powerful of these factors, relaxing the fundus with lower intragastric pressure, increasing the reservoir function of the proximal stomach, contracting the pyloric sphincter, and changing intestinal peristalsis from a propagated series of waves to segmenting activity.
The following examples are offered for purposes of illustration, and are not intended to limit the invention in any manner.
This example illustrates the controlled-release behavior of metformin hydrochloride, a highly soluble drug (whose solubility is approximately 35 %), from a polymeric matrix consisting of polyethylene oxide). Three different dose levels were prepared --systems designed to release 90 % of their drug contents at approximately 3 hours, 6 hours, and 8 hours, respectively.
Drug and polymer, with 0.5 % magnesium stearate as a tableting lubricant, were compressed into pellets measuring 7.2 mm diameter x 8.8 mm length and weighing 390 mg for samples designed for 3-hour and 6-hour release, and 7.4 mm diameter x 8.5 mm length and weighing 380 mg for samples designed for 8-hour release, and two pellets of a given type were incorporated into a single gelatin capsule. Thus, three different types of gelatin capsule were prepared as follows:
t~% - 3 hours:
metformin hydrochloride 250.00 mg POLYOX~ 1105, molecular weight 900,000 138.67 magnesium stearate 1.95 Totai: 390.62 mg t~% = 6 hours:
metformin hydrochloride 250.00 mg POLYOX~ Coagulant, molecular weight 5,000,000 138.67 magnesium stearate 1.95 Total: 390.62 mg t~% = 8 hours:
metformin hydrochloride 125.00 mg POLYOX~ 303, molecular weight 7,000,000 266.11 magnesium stearate 1.97 Total: 393.08 mg Release rate tests on each of these three formulations were performed in modified artificial gastric fluid by the following procedure.
Dissolution was performed in a USP Apparatus 2, modified to include a stainless steel cone (7/8 inch in height and 7/8 inch in diameter at the base) at the bottom of each 5 vessel, placed directly beneath the paddle shaft to eliminate the "dead zone" effect. A
paddle speed of 60 rpm and a bath temperature of 37.4°C were used. , The gelatin capsule was opened and the individual pellets and empty gelatin capsule were dropped into the dissolution vessel containing 900 mL of modified simulated gastric fluid (7 mL
of hydrochloric acid and 2 g of sodium chloride in 100 mL of deionized water; the enzyme 10 pepsin was omitted). Once the pellets had settled to the bottom of the vessel, the paddle rotation was initiated. Samples 5 mL in size were taken at specified time points, and the sample volumes were not replaced. The samples were diluted as necessary for quantitative analysis by HPLC.
The results are shown in FIG. 1, where the filled diamonds represent the t~%
__ 3 formulation, the x's represent the t~~ - 6 formulation, and the open circles represent the t~% = 8 formulation. The curves show that the t~~ value of the first formulation was fairly close to 3.5 hours, the t~% value of the second formulation was fairly close to 6.0 hours, and t~% value of the third formulation was fairly close to 7.5 hours.
This example illustrates the controlled-release behavior of captopril from a polymeric matrix consisting of polyethylene oxide), both with and without glyceryl monostearate (8% by weight). The formulations used were as follows:
1. Captopril 925.0 mg Polyethylene oxide) (POLYOX~ 301), molecular weight 4,000,000 4,075.0 Total 5,000.00 mg 2. Captopril 925.0 mg glyceryl monostearate 150.0 Polyethylene oxide) (POLYOX~ 301), molecular weight 4,000,000 3.925.0 Total 5,000.0 mg Each formulation was compressed into a tablet measuring 6.0 mm diameter x 6.7 mm length and weighing 180 mg. Release rate tests on each of the two tablets were performed in modified simulated gastric fluid by the procedure of Example 1, except that the paddle rotation speed was 30 rpm and the tablets were dropped directly into the dissolution vessel.
S The results are shown in FIG. 2, where the filled squares represent Formulation No. 1 consisting of captopril and polyethylene oxide) only, and the open circles represent Formulation No. 2 which further contained glyceryl monostearate.
This example illustrates the controlled-release behavior of captopril from a polymeric matrix of hydroxyethyl cellulose with the inclusion of glyceryl monostearate, but at varying pellet sizes. The formulation contained 19% captopril (all percents by weight) and 4. 8 % glyceryl monostearate in hydroxyethyl cellulose of molecular weight within the range of 1,000,000 to 1,500,000. The pellet sizes and weights were (a) 3.3 mm diameter x 3.S mm length at 3S mg (referred to herein as 3-mm tablets), (b) 4.3 nun 1S diameter x 4.9 mm length at 7S mg (referred to herein as 4-mm tablets), and (c) 6.3 mm diameter x 6.S mm length at 187 mg (referred to herein as 6-mm tablets).
Release rate tests on each of the three tablet sizes (fifteen of the 3-mm tablets, seven of the 4-mm tablets, and three of the 6-mm tablets) were performed using the procedures of Example 1, except that a weighted watchglass was used in place of the stainless steel cone, and analyses of the samples were performed by UV/Vis.
The results are shown in FIG. 3, where the filled squares represent the 3-mm pellets, the filled triangles the 4-mm pellets, and the filled circles the 6-mm pellets. This demonstrates the variation of pellet size as a further means of varying the release pattern, the larger pellets having less surface area.
This example further illustrates the controlled release of metformin hydrochloride, using a higher drug loading, and various polymers and combinations of polymers. The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 4 where the results are plotted, were as follows (all percentages are by weight):
Filled circles: 79.6% metformin HCI; 20% polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000); 0.4% magnesium stearate. Pellet dimensions 6.04 mm diameter x 9.48 mm length; containing approximately 478 mg metformin HCI.
Filled squares: 79.6% metformin HCI; 20% xanthan gum (KELTROL~ F, Kelco, Div.
of Merck & Co., Inc., San Diego, California, USA); 0.4% magnesium stearate.
Pellet dimensions 6.06 mm diameter x 9.40 mm length; containing approximately 483 mg metformin HCI.
Plus signs: 79.6% metformin HCI; 20% hydroxypropylmethyl cellulose (BENECEL~
824, Aqualon Co., Wilmington, Delaware, USA), viscosity (2%, 20°C) 11,000 to 15,000 cps; 0.4% magnesium stearate. Pellet dimensions 6.06 mm diameter x 9.49 mm length; containing approximately 480 mg metformin HCI.
Open diamonds: 79.6 % metformin HCI; 5 % hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 15% polyethylene oxide (POLYOX~ 303, molecular weight 7,000,000); 0.4% magnesium stearate. Pellet dimensions 6.06 mm diameter x 9.60 mm length; containing approximately 480 mg metformin HCI.
x's: 79.6% metformin HCI, 18.05% xanthan gum (KELTROL~ F); 1.99% WATER
LOCK~ D-223 (starch graft poly(2-propenamide-co-2-propenoic acid)), mixed sodium and aluminum salts, Grain Processing Corporation, Muscatine, Iowa, USA); 0.4 % magnesium stearate. Pellet dimensions were 6.06 mm diameter x 9.24 mm length; containing approximately 476 mg metformin HCI total.
This example further illustrates the controlled release of metformin hydrochloride from a single capsule-shaped tablet. The procedures used were the same as those described above, and the resulting curve is plotted in FIG. 5. The formulation was as follows (all percentages are by weight): 64 % metformin HCI; 35.5 %
polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000); 0.5 % magnesium stearate; plus an additional 2 % OPADRY~ Clear coating (hydroxypropyl methylcellulose, Colorcon, West Point, Pennsylvania, USA). The tablet dimensions were 6.48 mm diameter x 7.20 mm height x 19.21 mm length, and contained approximately 506 mg metformin HCl per tablet.
This example further illustrates the controlled release of captopril, using various polymers and combinations of polymers. The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 6 where the results are plotted, were as follows (all percentages are by weight):
Plus signs: 80 % captopril; 20 % hydroxypropylmethyl cellulose (BENECEL~ 824, viscosity (2%, 20°C) 11,000 to 15,000 cps). Pellet dimensions: 6.03 mm diameter x 9.25 mm length, 2 pellets weighing 293 mg each, containing approximately 468.6 mg captopril total.
Filled diamonds: 80% captopril; 20% xanthan gum (KELTROL~ F}. Pellet dimensions:
6.04 mm diameter x 9.18 mm length, 2 pellets weighing 299 mg each, containing approximately 477.8 mg captopril total.
Filled triangles: 80% captopril; 20% hydroxyethyl cellulose (250HX, molecular weight 1,000,000}. Pellet dimensions: 6.03 mm diameter x 9.53 mm length, 2 pellets weighing 299 mg each, containing approximately 478.2 mg captopril total.
Open circles: 80% captopril; 20% polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000). Pellet dimensions: 6.04 mm diameter x 9.59 mm length, 2 pellets weighing 301 mg each, containing approximately 481.6 mg captopril total.
Filled squares: 80% captopril; 20% carboxymethyl cellulose (12M31P, molecular weight 250,000). Pellet dimensions: 6.04 mm diameter x 9.18 mm length, 2 pellets weighing 299 mg each, containing approximately 477.6 mg captopril total.
Open triangles: 79.93 % captopril; 10.03 % hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 10.04% xanthan gum (KELTROL~ F). Pellet dimensions:
6.04 mm diameter x 9.26 mm length, 2 pellets weighing 296 mg each, containing approximately 478.2 mg captopril total.
x's: 79.96% captopril; 10.03% hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 10.01 % polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000). Pellet dimensions: 6.04 mm diameter x 9.41 mm length, 2 pellets weighing 297 mg each, containing approximately 483 mg captopril total.
Dashes: 80 % captopril; 10 % hydroxyethyl cellulose (250HX, molecular weight 1,000,000); 10% hydroxypropylmethyl cellulose (BENECEL~ 824, viscosity (2%, 20°C) 11,000 to 15,000 cps). Pellet dimensions: 6.04 mm diameter x 9.41 mm length, 2 pellets weighing 298 mg each, containing approximately 476.6 mg captopril total.
Open diamonds: 79.96 % captopril; 18.05 % xanthan gum (KELTROL~ F); 1.99 WATERLOCK~ D-223. Pellet dimensions: 6.04 mm diameter x 9.16 mm length, 2 pellets weighing 297 mg each, containing approximately 475 mg captopril total.
This example presents further data on metformin hydrochloride formulations, illustrating the effect of lower drug loadings than those used in the preceding examples.
The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 7 where the results are plotted, were as follows (all percentages are by weight):
Filled squares: 32.5% metformin HCI; 67% polyethylene oxide) (POLYOX~ 303, molecular weight 7,000,000); 0.5 % magnesium stearate. Pellet dimensions 6.62 mm diameter x 10.40 mm length, 2 pellets weighing 400 mg each, containing approximately 260 mg metformin HCl total.
Open circles: 32.5 % metformin HCI; 67 % xanthan gum (KELTROL~ F); 0.5 magnesium stearate. Pellet dimensions 6.65 mm diameter x 9.28 mm length; 2 pellets weighing 401 mg each, containing approximately 261 mg metformin HCl total.
This example illustrates the sustained release of vancomycin hydrochloride from various polymers. The procedures used were the same as those described above, and the formulations together with the symbols used in FIG. 8 where the results are plotted, were as follows (all percentages are by weight):
Open squares: 31.5 % vancomycin hydrochloride; 68 % polyethylene oxide) (POLYOX
303, molecular weight 7,000,000); 0.5 % magnesium stearate. Pellet dimensions:
6.59 mm diameter x 10.23 mm length, 2 pellets weighing 403 mg each, containing approximately 253 mg vancomycin hydrochloride total.
5 Open triangles: 31.5 % vancomycin hydrochloride; 68 % polyethylene oxide) (POLYOX m 301, molecular weight 4,000,000); 0.5% magnesium stearate. Pellet dimensions:
6.59 mm diameter x 10.28 mm length, 2 pellets weighing 402 mg each, containing approximately 253 mg vancomycin hydrochloride total.
x's: 31.5% vancomycin hydrochloride; 68% hydroxypropyl methylcellulose (BENECEL~
10 824, viscosity 11,000-15,000 cps (2% solution at 20°C)); 0.5%
magnesium stearate. Pellet dimensions: 6.59 mm diameter x 10.10 mm length, 2 pellets weighing 405 mg each, containing approximately 255 mg vancomycin hydrochloride total.
Open circles: 31.5% vancomycin hydrochloride; 68% xanthan gum (KELTROL~ F);
15 0.5 % magnesium stearate. Pellet dimensions: 6.62 mm diameter x 9.77 mm length, 2 pellets weighing 401 mg each, containing approximately 253 mg vancomycin hydrochloride total.
Filled squares: 62.5 % vancomycin hydrochloride; 37 % polyethylene oxide) (POLYOX
303, molecular weight 7,000,000); 0.5 % magnesium stearate. Pellet dimensions:
6.60 mm diameter x 10.01 rnm length, 2 pellets weighing 409 mg each, containing approximately 508 mg vancomycin hydrochloride total.
In the prior art, vancomycin and its salts are administered by injection, due to poor absorption when administered orally. By providing for all or at least a portion of the total administered amount to be delivered by controlled delivery in the gastric retentive system of this invention, that portion so delivered is directed to the proximal portion of the small intestine, the most efficient site for absorption of this drug, resulting in an enhanced absorption from the oral dosage form of the invention.
The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the components, additives, proportions, methods of formulation, and other parameters of the invention can be modified further or substituted in various ways without departing from the spirit and scope of the invention.
Claims (23)
1. A controlled-release oral drug dosage form for releasing a drug, one part by weight of said drug being dissoluable in less than ten parts by weight of water, said dosage form comprising a solid polymeric matrix in which said drug is dispersed at a weight ratio of drug to polymer of about 80:20 or less, said polymeric matrix being one that swells to at least about twice its volume upon imbibition of water, that releases said drug into gastric fluid by the dissolution and diffusion of said drug out of said matrix by said gastric fluid, that upon immersion in gastric fluid retains at least about 40% of said drug one hour after such immersion and releases substantially all of said drug within about eight hours after such immersion, that remains substantially intact until all of said drug is released, and that promotes retention of the dosage form in the stomach during the fed mode.
2. A controlled-release oral drug dosage form for releasing a drug, one part by weight of said drug being dissoluable in less than ten parts by weight of water, said dosage form comprising a solid polymeric matrix in which said drug is dispersed at a weight ratio of drug to polymer of about 80:20 or less, said dosage form being one that swells to a size large enough to promote retention in the stomach during the fed mode, that releases said drug into gastric fluid by the dissolution and diffusion of said drug out of said matrix by said gastric fluid, that upon immersion in gastric fluid retains at least about 40% of said drug one hour after such immersion.
3. A dosage form of claim 1 or 2 in which one part by weight of said drug is dissoluable in less than about five parts by weight of water.
4. A dosage form of claim 1 or 2 in which one part by weight of said drug is dissoluable in less than about three parts by weight of water.
5. A dosage form of any one of claims 1 to 4 in which said drug is a member selected from the group consisting of metformin hydrochloride, vancomycin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, and ticlopidine hydrochloride.
6. A dosage form of any one of claims 1 to 4 in which said drug is metformin hydrochloride.
7. A dosage form of any one of claims 1 to 4 in which said drug is sertraline hydrochloride.
8. A dosage form of any one of claims 1 to 4 in which said drug is captopril.
9. A dosage form of any one of claims 1 to 4 in which said drug is vancomycin hydrochloride.
10. A dosage form of any one of claims 1 to 9 in which said polymeric matrix is formed of a polymer selected from the group consisting of poly(ethylene oxide), xanthan gum, cellulose, alkyl-substituted celluloses, and crosslinked polyacrylic acids.
11. A dosage form of any one of claims 1 to 9 in which said polymeric matrix is formed of a polymer selected from the group consisting of poly(ethylene oxide), xanthan gum, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose.
12. A dosage form of any one of claims 1 to 9 in which said polymeric matrix is formed of poly(ethylene oxide) at a molecular weight of at least about 4,500,000.
13. A dosage form of any one of claims 1 to 9 in which said polymeric matrix is formed of poly(ethylene oxide) at a molecular weight in the range of about 4,500,000 to about 10,000,000.
14. A dosage form of any one of claims 1 to 9 in which said polymeric matrix is formed of poly(ethylene oxide) at a molecular weight in the range of about 5,000,000 to about 8,000,000.
15. A dosage form of any one of claims 1 to 14 in which said weight ratio of drug to polymer is from about 15:85 to about 80:20.
16. A dosage form of any one of claims 1 to 14 in which said weight ratio of drug to polymer is from about 30:70 to about 80:20.
17. A dosage form of any one of claims 1 to 14 in which said weight ratio of drug to polymer is from about 30:70 to about 70:30.
18. A dosage form of any one of claims 1 to 17 in which said polymeric matrix upon immersion in gastric fluid retains at least about 50% of said drug one hour after such immersion.
19. A dosage form of any one of claims 1 to 17 in which said polymeric matrix upon immersion in gastric fluid retains at least about 60% of said drug one hour after such immersion.
20. A dosage form of any one of claims 1 to 17 in which said polymeric matrix upon immersion in gastric fluid retains at least about 80% of said drug one hour after such immersion.
21. A dosage form of any one of claims 1 to 20 further comprising a hydrophobic additive formulated with said drug to further retard the release of said drug to said gastric fluid.
22. A dosage form of any one of claims 1 to 21 in which said polymeric matrix consists of two cylindrical tablets, each measuring about 9 mm to about 12 mm in length and about 6.5 mm to about 7 mm in diameter.
23. A dosage form of any one of claims 1 to 21 in which said polymeric matrix consists of a single elongated tablet measuring about 18 mm to about 22 mm in length, about 6.5 mm to about 7.8 mm in width, and about 6.2 to 7.5 mm in height.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87050997A | 1997-06-06 | 1997-06-06 | |
| US08/870,509 | 1997-06-06 | ||
| PCT/US1998/011302 WO1998055107A1 (en) | 1997-06-06 | 1998-06-05 | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2290624A1 CA2290624A1 (en) | 1998-12-10 |
| CA2290624C true CA2290624C (en) | 2006-12-05 |
Family
ID=25355537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002290624A Expired - Lifetime CA2290624C (en) | 1997-06-06 | 1998-06-05 | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6340475B2 (en) |
| EP (1) | EP0998271B3 (en) |
| JP (1) | JP4083818B2 (en) |
| AT (1) | ATE302597T1 (en) |
| AU (1) | AU729529B2 (en) |
| CA (1) | CA2290624C (en) |
| DE (1) | DE69831335T3 (en) |
| ES (1) | ES2248908T7 (en) |
| HK (1) | HK1027298A1 (en) |
| PT (1) | PT998271E (en) |
| WO (1) | WO1998055107A1 (en) |
Families Citing this family (339)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| JP4083818B2 (en) | 1997-06-06 | 2008-04-30 | ディポメド，インコーポレイティド | Gastric retentive oral drug dosage form for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| EA003101B1 (en) * | 1998-03-19 | 2002-12-26 | Бристол-Майерз Сквибб Компани | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| ATE340563T1 (en) | 2000-02-04 | 2006-10-15 | Depomed Inc | SHELL AND CORE TYPE DOSAGE FORM WITH A RELEASE OF ACTIVE INGREDIENTS APPROACHING TO THE ZERO ORDER |
| US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| EP1313486A1 (en) * | 2000-02-29 | 2003-05-28 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
| EP1267840B1 (en) * | 2000-03-28 | 2009-06-03 | Sandoz AG | Granulated particles with masked taste |
| US6488962B1 (en) * | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US6881420B2 (en) * | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| DE10031043A1 (en) | 2000-06-26 | 2002-02-14 | Bayer Ag | Retarded preparations of quinolone antibiotics and process for their preparation |
| WO2002026214A1 (en) * | 2000-09-29 | 2002-04-04 | Solvay Pharmaceuticals B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| WO2002028181A1 (en) * | 2000-10-02 | 2002-04-11 | Usv Limited | Sustained release pharmaceutical compositions containing metformin and method of its production |
| WO2002030392A2 (en) | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| FR2816840B1 (en) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME |
| US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
| ES2231717T3 (en) * | 2001-05-03 | 2005-05-16 | F. Hoffmann-La Roche Ag | PHARMACEUTICAL DOSAGE FORM OF MELFINAVIR AMORFO MESILATE. |
| KR20040020056A (en) * | 2001-05-29 | 2004-03-06 | 디포메드 디벨롭먼트 리미티드 | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
| WO2003004009A1 (en) * | 2001-07-02 | 2003-01-16 | Geneva Pharmaceuticals, Inc. | Pharmaceutical composition |
| BR0211317A (en) * | 2001-07-04 | 2004-12-14 | Sun Pharmaceutical Ind Ltd | System for controlled drug release through gastric retention |
| US20030129234A1 (en) * | 2001-07-06 | 2003-07-10 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone |
| US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| US9820982B2 (en) * | 2001-07-06 | 2017-11-21 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| ITMI20011457A1 (en) * | 2001-07-09 | 2003-01-09 | Valpharma Sa | MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING BUPROPIONEHC1 AS ACTIVE SUBSTANCE |
| US20040219186A1 (en) * | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US20030091635A1 (en) * | 2001-09-26 | 2003-05-15 | Baichwal Anand R. | Opioid formulations having reduced potential for abuse |
| PE20030527A1 (en) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT |
| US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
| US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| WO2003035039A1 (en) | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2466032A1 (en) * | 2001-10-29 | 2003-05-08 | Laure Patricia Ouadji Njiki | Methods and dosage forms for improving the bioavailability of therapeutic agents |
| PL369328A1 (en) * | 2001-11-06 | 2005-04-18 | Ranbaxy Laboratories Limited | Controlled release tablets of metformin |
| US6667054B2 (en) * | 2001-12-05 | 2003-12-23 | Bernard Charles Sherman | Metformin hydrochloride tablets |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
| US8323692B2 (en) | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
| IL164077A0 (en) * | 2002-03-22 | 2005-12-18 | Cilag Ag | Sustained release formulation of tramadol |
| KR101061351B1 (en) | 2002-04-09 | 2011-08-31 | 플라멜 테크놀로지스 | Oral Suspension of Active Ingredient Microcapsules |
| WO2003099214A2 (en) * | 2002-05-23 | 2003-12-04 | Andrx Corporation | Biguanide formulations |
| US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| GB0214013D0 (en) * | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| PA8578501A1 (en) * | 2002-07-25 | 2005-02-04 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| CA2494281A1 (en) * | 2002-08-02 | 2004-02-12 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US8268352B2 (en) * | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| JP2006501310A (en) * | 2002-08-29 | 2006-01-12 | アクティブバイオティクス インコーポレイティッド | Methods and reagents for treating Clostridium difficile infection and related diseases |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US20040180086A1 (en) * | 2002-10-11 | 2004-09-16 | Zebunnissa Ramtoola | Gastro-retentive levodopa delivery form |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
| US20040086566A1 (en) * | 2002-11-04 | 2004-05-06 | Alpharma, Inc. | Waxy matrix dosage forms |
| US20040131672A1 (en) * | 2003-01-07 | 2004-07-08 | Nilobon Podhipleux | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
| AU2004204825B2 (en) | 2003-01-13 | 2007-07-19 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
| BRPI0408323A (en) * | 2003-03-14 | 2006-03-07 | Nirmal Mulye | process for the preparation of prolonged release tablets |
| CA2520321A1 (en) * | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
| EP1638529B1 (en) * | 2003-06-16 | 2016-08-10 | ANDRX Pharmaceuticals, LLC. | Oral extended-release composition |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| JP2006528185A (en) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
| US8313776B2 (en) * | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
| US8313775B2 (en) * | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
| DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE102004032051A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
| DE10361596A1 (en) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
| DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004020220A1 (en) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
| CA2524300C (en) * | 2003-08-08 | 2008-10-28 | Biovail Laboratories International Srl | Modified-release tablet of bupropion hydrochloride |
| EP1653925A1 (en) * | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
| JP2007502294A (en) * | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
| EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
| CA2535780A1 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| JP2007513869A (en) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
| EP1680098A4 (en) * | 2003-11-04 | 2012-06-13 | Supernus Pharmaceuticals Inc | Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms |
| US20050142187A1 (en) * | 2003-12-24 | 2005-06-30 | Treacy Donald J.Jr. | Enhanced absorption of modified release dosage forms |
| WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
| KR100772980B1 (en) | 2004-04-01 | 2007-11-02 | 한미약품 주식회사 | Controlled release formulation for oral administration of metformin |
| AU2005265031A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| DE102004032049A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
| DE102004032103A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
| WO2006014427A1 (en) * | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
| JP4971159B2 (en) * | 2004-08-13 | 2012-07-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sustained release pellet preparation containing pramipexole or a pharmaceutically acceptable salt thereof, its production method and use |
| PT1789021E (en) | 2004-08-13 | 2011-12-22 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
| KR100760430B1 (en) * | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof |
| DE102005005449A1 (en) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
| AU2006242535B2 (en) * | 2005-04-29 | 2012-08-09 | Merck Sharp & Dohme Corp. | Therapeutic compositions |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
| US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7544373B2 (en) | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7541347B2 (en) | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
| US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| JP5095615B2 (en) * | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | Modified release of bupropion salt |
| JP5490409B2 (en) | 2005-07-11 | 2014-05-14 | コルトリア・コーポレーション | Preparations for the treatment of lipoprotein abnormalities comprising statins and methylnicotinamide derivatives |
| US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
| WO2007020508A1 (en) * | 2005-08-12 | 2007-02-22 | Ferring International Center S.A. | Method and device for dividing granules |
| BRPI0615410A2 (en) * | 2005-08-30 | 2013-02-13 | Nicholas Piramal India Ltd | metformin prolonged release pharmaceutical composition and process for producing metformin |
| KR20080080094A (en) | 2005-10-14 | 2008-09-02 | 하. 룬트벡 아크티에 셀스카브 | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| US20090098202A1 (en) * | 2006-02-10 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Extended Release Formulation |
| US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
| AU2007242077B2 (en) * | 2006-04-26 | 2013-11-14 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
| AU2013202441B2 (en) * | 2006-04-26 | 2016-02-25 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
| US20090011018A1 (en) * | 2006-12-28 | 2009-01-08 | Astellas Pharma Inc., | Sustained release formulation for tacrolimus |
| US8058312B2 (en) | 2007-01-29 | 2011-11-15 | Hanall Biopharma Co., Ltd. | N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| EP2139498B1 (en) | 2007-03-22 | 2015-03-18 | Dendreon Corporation | Methods for detecting a natural killer (nk) cell-mediated immune response and an increase in nk cell activity |
| US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
| US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
| WO2009004592A1 (en) * | 2007-07-03 | 2009-01-08 | Wockhardt Research Centre | Vancomycin compositions |
| BRPI0821732A2 (en) | 2007-12-17 | 2015-06-16 | Labopharm Inc | Controlled release formulations, solid dosage form, and use of controlled release formulation |
| JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
| US20090246276A1 (en) | 2008-01-28 | 2009-10-01 | Graham Jackson | Pharmaceutical Compositions |
| AU2009210641A1 (en) * | 2008-02-05 | 2009-08-13 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor |
| JP2011513408A (en) * | 2008-03-04 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor |
| CA2720108C (en) * | 2008-03-11 | 2016-06-07 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| JP5114281B2 (en) * | 2008-04-17 | 2013-01-09 | 塩野義製薬株式会社 | Tablets containing vancomycin hydrochloride |
| EP2273983B1 (en) * | 2008-05-09 | 2016-07-20 | Grünenthal GmbH | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| EP3782611B1 (en) | 2008-05-15 | 2022-07-06 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| ZA200903854B (en) | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
| US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
| WO2010026467A2 (en) | 2008-09-04 | 2010-03-11 | Torrent Pharmaceuticals Ltd. | Controlled release dosage form of high solubility active ingredient |
| NZ592276A (en) | 2008-09-18 | 2012-12-21 | Purdue Pharma Lp | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID |
| WO2010038237A2 (en) | 2008-09-22 | 2010-04-08 | Rubicon Research Private Limited | Compositions exhibiting delayed transit through the gastrointestinal tract |
| MX2011003749A (en) | 2008-10-08 | 2011-09-01 | Bioplus Life Sciences Pvt Ltd | Sustained release drug delivery system. |
| EP2367541B1 (en) | 2008-12-16 | 2014-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| CA2758976C (en) | 2009-04-20 | 2015-02-03 | Alain Baron | Chemosensory receptor ligand-based therapies |
| AU2010245932B2 (en) | 2009-05-05 | 2015-08-06 | Board Of Regents, The University Of Texas System | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
| ES2560210T3 (en) | 2009-07-22 | 2016-02-17 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opiates |
| JP5667183B2 (en) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Controlled release dosage form with heat melt extrusion |
| US20110052700A1 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride |
| WO2011026125A2 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
| US20110104273A1 (en) * | 2009-11-05 | 2011-05-05 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine |
| CA2783342A1 (en) * | 2009-12-08 | 2011-06-16 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for extended release of polypeptides |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| ES2606227T3 (en) * | 2010-02-03 | 2017-03-23 | Grünenthal GmbH | Preparation of a pharmaceutical powder composition by an extruder |
| JP2010120967A (en) * | 2010-02-24 | 2010-06-03 | Shionogi & Co Ltd | Tablet containing vancomycin hydrochloride |
| ES2665467T3 (en) | 2010-03-29 | 2018-04-25 | Astellas Pharma Inc. | Modified Release Pharmaceutical Composition |
| EP2561892B1 (en) * | 2010-03-31 | 2015-05-06 | Mochida Pharmaceutical Co., Ltd. | Easily dosable solid preparation |
| US8581001B2 (en) | 2010-04-16 | 2013-11-12 | Codman & Shurtleff | Metformin-cysteine prodrug |
| EP2603215A4 (en) | 2010-08-11 | 2015-08-05 | Philadelphia Health & Educatio | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
| KR20130137627A (en) | 2010-09-02 | 2013-12-17 | 그뤼넨탈 게엠베하 | Tamper resistant dosage form comprising an anionic polymer |
| RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
| EP2621487B1 (en) | 2010-09-28 | 2017-05-03 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| JP2013540156A (en) | 2010-10-19 | 2013-10-31 | エルセリクス セラピューティクス インコーポレイテッド | Chemosensory receptor ligand based therapy |
| ME02554B (en) | 2010-11-08 | 2017-02-20 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
| JP6076913B2 (en) | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | Methods for inhibiting metastasis from cancer |
| BR112013017411B1 (en) | 2011-01-07 | 2022-03-22 | Anji Pharma (Us) Llc | Use of a composition comprising metformin or a salt thereof |
| UY33937A (en) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS |
| US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
| US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
| US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
| AR087359A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO |
| WO2013017234A1 (en) | 2011-07-29 | 2013-02-07 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| KR101870004B1 (en) | 2011-09-30 | 2018-06-22 | 모찌다 세이야쿠 가부시끼가이샤 | Easy-to-take solid preparation |
| JP6162709B2 (en) | 2011-11-01 | 2017-07-12 | セルジーン コーポレイション | Methods of treating cancer using oral preparations of cytidine analogs |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| MX359634B (en) | 2011-12-21 | 2018-10-03 | Novira Therapeutics Inc | Hepatitis b antiviral agents. |
| MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| ES2692944T3 (en) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US9388126B2 (en) | 2012-07-19 | 2016-07-12 | Drexel University | Sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| ES2689906T3 (en) | 2012-08-09 | 2018-11-16 | Dynamis Therapeutics, Inc. | Meglumine to reduce high triglyceride levels |
| US20140150787A1 (en) * | 2012-12-04 | 2014-06-05 | Civitas Therapeutics, Inc. | Devices and methods for puncturing a capsule to release a powdered medicament therefrom |
| PT2941233T (en) | 2013-01-07 | 2020-11-13 | Univ Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| EP3033075A1 (en) | 2013-03-26 | 2016-06-22 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof |
| US20150366863A1 (en) | 2013-03-28 | 2015-12-24 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| CA2914365C (en) | 2013-06-05 | 2022-03-15 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CA2917149C (en) | 2013-07-02 | 2021-02-02 | Cineole Corp., Llc | Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EA032465B1 (en) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof |
| KR101597004B1 (en) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor |
| EP3074049B1 (en) | 2013-11-26 | 2020-05-06 | Yale University | Novel cell-penetrating compositions and methods using same |
| WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015089049A1 (en) | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
| US9982010B2 (en) | 2014-04-07 | 2018-05-29 | Women & Infants Hospital Of Rhode Island | 7-dehydrocholesterol derivatives and methods using same |
| CN106572980A (en) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| CA2952405A1 (en) * | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for stabilizing the same |
| CA2968215A1 (en) | 2014-08-20 | 2016-02-25 | Yale University | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
| KR20170042598A (en) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| BR112017017729A2 (en) | 2015-02-20 | 2018-04-10 | Osmotica Kereskedelmi Es Szolgaltato Kft | gaba receptor agonist controlled release oral dosage form |
| US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
| KR20170139158A (en) | 2015-04-24 | 2017-12-18 | 그뤼넨탈 게엠베하 | Immediate release and solvent extraction inhibition modulated dosage form |
| WO2016182968A1 (en) | 2015-05-08 | 2016-11-17 | Brown University | Novel syringolin analogues and methods of making and using same |
| CA2984947A1 (en) | 2015-05-19 | 2016-11-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| WO2016201288A1 (en) | 2015-06-12 | 2016-12-15 | Brown University | Novel antibacterial compounds and methods of making and using same |
| AU2016285656B2 (en) | 2015-06-30 | 2020-02-27 | Neurad Ltd. | Novel breathing control modulating compounds, and methods of making and using same |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| BR112018007447B1 (en) | 2015-10-15 | 2023-12-05 | Celgene Corporation | USE OF 2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2- (TRIFLUOROMETHYL) PIRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN -2-IL)AMINO]PROPAN2-OL AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND |
| JP2018534288A (en) | 2015-10-15 | 2018-11-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | Combination therapy for the treatment of malignant tumors |
| KR20180067658A (en) | 2015-10-15 | 2018-06-20 | 아지오스 파마슈티컬스 아이엔씨. | Combination Therapy for the Treatment of Malignant Tumors |
| JP6970667B2 (en) | 2015-10-28 | 2021-11-24 | イエール ユニバーシティ | Quinoline amide and its usage |
| EP3377105A4 (en) | 2015-11-20 | 2019-04-24 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
| EP3383433A1 (en) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CA3015757A1 (en) | 2016-02-26 | 2017-08-31 | Agios Pharmaceuticals, Inc. | Idh1 inhibitors for the treatment of haematological malignancies and solid tumours |
| CN109310653A (en) | 2016-03-17 | 2019-02-05 | 硫创治疗公司 | For controlling the composition of release cysteamine and systematic treating cysteamine condition responsive |
| US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
| US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
| US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| US20180064817A1 (en) * | 2016-04-23 | 2018-03-08 | Jayendrakumar Dasharathlal Patel | Tamper Resistant Pharmaceutical Composition |
| US20190119364A1 (en) | 2016-04-29 | 2019-04-25 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
| US20210330599A1 (en) | 2016-08-01 | 2021-10-28 | University Of Rochester | Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use |
| US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| EP3493829B1 (en) | 2016-08-05 | 2024-04-17 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| SG11201901452UA (en) | 2016-09-01 | 2019-03-28 | Mebias Discovery Llc | Substituted ureas and methods of making and using same |
| SG11201902944TA (en) | 2016-11-07 | 2019-05-30 | Arbutus Biopharma Corp | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| WO2018136766A1 (en) | 2017-01-19 | 2018-07-26 | Temple University-Of The Commonwealth System Of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
| MA49014A (en) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | DIHYDROINDENE-4-CARBOXAMIDES SUBSTITUTED, THEIR ANALOGUES AND PROCESSES FOR THEIR CORRESPONDING USE |
| JP7108018B2 (en) | 2017-04-17 | 2022-07-27 | イエール ユニバーシティ | Compounds, compositions and methods for treating or preventing acute lung injury |
| US11229653B2 (en) | 2017-05-05 | 2022-01-25 | Celgene Corporation | Methods of treatment of myeloproliferative neoplasm |
| CN110996922A (en) | 2017-06-16 | 2020-04-10 | 卡希夫生物科学有限责任公司 | Gastric retentive dosage forms for sustained drug delivery |
| US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
| BR112019028278A2 (en) | 2017-07-17 | 2020-07-14 | Eli Lilly And Company | pharmaceutical compositions |
| WO2019018158A1 (en) | 2017-07-17 | 2019-01-24 | Eli Lilly And Company | Pharmaceutical compositions |
| AU2018306726B2 (en) | 2017-07-28 | 2023-08-03 | Yale University | Anticancer drugs and methods of making and using same |
| CN111032019B (en) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | Cholestyramine granules, oral cholestyramine preparation and application thereof |
| KR20200072478A (en) | 2017-09-08 | 2020-06-22 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | Compounds, compositions and methods for treatment or prevention of HER-driven drug-resistant cancer |
| US11612576B2 (en) | 2017-09-20 | 2023-03-28 | Thiogenesis Therapeutics, Inc. | Methods for the treatment of cysteamine sensitive disorders |
| AU2018360383A1 (en) | 2017-11-02 | 2020-05-21 | Natureceuticals Sdn. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
| EP3716985A1 (en) | 2017-11-27 | 2020-10-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Compounds, compositions, and methods for treating and/or preventing periodontal disease |
| EP3737353A1 (en) | 2017-12-18 | 2020-11-18 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| CN112004520A (en) | 2017-12-18 | 2020-11-27 | 特瑞斯制药公司 | Modified release drug powder compositions comprising a gastric retentive raft forming system with triggered pulsed drug release |
| US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
| WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
| TW201944989A (en) | 2018-01-24 | 2019-12-01 | 洛克斐勒大學 | Antibacterial compounds, compositions thereof, and methods using same |
| ES2948788T3 (en) | 2018-01-29 | 2023-09-19 | Univ Duke | Compositions and methods to improve the bioavailability of 5-hydroxytryptophan |
| EP3802524A1 (en) | 2018-05-29 | 2021-04-14 | Cersci Therapeutics, Inc. | Compounds for pain treatment, compositions comprising same, and methods of using same |
| JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
| JP7391048B2 (en) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11229606B2 (en) | 2018-06-18 | 2022-01-25 | Amneal Complex Products Research Llc | Extended release compositions comprising pyridostigmine |
| AU2019289132A1 (en) | 2018-06-19 | 2021-02-04 | Nanyang Technological University | Formulations of 5-hydroxy tryptophan (5-HTP) for better bioavailability for various indications |
| KR20210024032A (en) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | Crystalline variant of odebiccibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| MX2021003653A (en) | 2018-10-11 | 2021-06-23 | Sanifit Therapeutics S A | Inositol phosphates for the treatment of ectopic calcification. |
| US20210403452A1 (en) | 2018-11-02 | 2021-12-30 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| US20220017489A1 (en) * | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| TWI827760B (en) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
| AU2020213713A1 (en) | 2019-01-30 | 2021-07-22 | Sanifit Therapeutics, S.A. | Inositol phosphate compounds for use in increasing tissular perfusion |
| WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
| US20200246317A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| KR102186704B1 (en) * | 2019-02-18 | 2020-12-04 | (주)아이엠디팜 | A sustained-release lipid pre-concentrate and a sustained-release injectable pharmaceutical composition in the form of lipid solution comprising the same |
| WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
| US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
| EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
| CN114761018A (en) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | Benzothiadiazepine compounds and their use as bile acid modulators |
| MX2022006731A (en) | 2019-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators. |
| JP2023504643A (en) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| MX2022015772A (en) | 2020-06-09 | 2023-05-19 | Inozyme Pharma Inc | Soluble enpp1 or enpp3 proteins and uses thereof. |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| KR20230117393A (en) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | Benzothia(di)azepine compounds and their use as bile acid regulators |
| EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
| EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
| CN116801868A (en) | 2021-07-30 | 2023-09-22 | 埃维西亚治疗公司 | Gastric retention dosage form of 5-hydroxytryptophan |
| WO2023064598A1 (en) | 2021-10-14 | 2023-04-20 | Evecxia Therapeutics, Inc. | A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
| WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
| WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
| WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863981A (en) * | 1986-06-30 | 1989-09-05 | Ciba-Geigy Corporation | Synergistic mixture of stabilizers |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| CA2132012C (en) | 1992-03-25 | 2003-04-22 | John W. Shell | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| DE4432757A1 (en) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmaceutical preparation containing metformin and process for its preparation |
| ATE214596T1 (en) * | 1995-04-14 | 2002-04-15 | Pharma Pass | SOLID COMPOSITIONS CONTAINING A NON-AMORPHOUS ACTIVE SUBSTANCE AND POLYETHYLENE OXIDE |
| EP0761209A3 (en) * | 1995-09-01 | 1998-02-04 | J.B. Chemicals & Pharmaceuticals Ltd. | Controlled release formulations of ranitidine |
| US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| JP4083818B2 (en) | 1997-06-06 | 2008-04-30 | ディポメド，インコーポレイティド | Gastric retentive oral drug dosage form for controlled release of highly soluble drugs |
-
1998
- 1998-06-05 JP JP50275699A patent/JP4083818B2/en not_active Expired - Lifetime
- 1998-06-05 DE DE69831335.6T patent/DE69831335T3/en not_active Expired - Lifetime
- 1998-06-05 CA CA002290624A patent/CA2290624C/en not_active Expired - Lifetime
- 1998-06-05 WO PCT/US1998/011302 patent/WO1998055107A1/en active IP Right Grant
- 1998-06-05 AU AU81386/98A patent/AU729529B2/en not_active Expired
- 1998-06-05 PT PT98931204T patent/PT998271E/en unknown
- 1998-06-05 AT AT98931204T patent/ATE302597T1/en active
- 1998-06-05 EP EP98931204.6A patent/EP0998271B3/en not_active Expired - Lifetime
- 1998-06-05 ES ES98931204.6T patent/ES2248908T7/en active Active
-
1999
- 1999-03-29 US US09/282,233 patent/US6340475B2/en not_active Expired - Lifetime
-
2000
- 2000-10-16 HK HK00106550A patent/HK1027298A1/en not_active IP Right Cessation
-
2001
- 2001-11-20 US US09/990,061 patent/US20020051820A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2248908T3 (en) | 2006-03-16 |
| EP0998271B3 (en) | 2014-10-29 |
| DE69831335D1 (en) | 2005-09-29 |
| CA2290624A1 (en) | 1998-12-10 |
| US20020051820A1 (en) | 2002-05-02 |
| AU729529B2 (en) | 2001-02-01 |
| EP0998271B1 (en) | 2005-08-24 |
| HK1027298A1 (en) | 2001-01-12 |
| EP0998271A1 (en) | 2000-05-10 |
| PT998271E (en) | 2005-10-31 |
| WO1998055107A1 (en) | 1998-12-10 |
| JP2000513028A (en) | 2000-10-03 |
| AU8138698A (en) | 1998-12-21 |
| DE69831335T3 (en) | 2015-01-15 |
| JP4083818B2 (en) | 2008-04-30 |
| DE69831335T2 (en) | 2006-06-08 |
| ATE302597T1 (en) | 2005-09-15 |
| US6340475B2 (en) | 2002-01-22 |
| ES2248908T7 (en) | 2014-11-24 |
| US20010018070A1 (en) | 2001-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2290624C (en) | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs | |
| CA2364845C (en) | Extending the duration of drug release within the stomach during the fed mode | |
| JP5133495B2 (en) | Optimal polymer blend for gastroretentive tablets | |
| US9597338B2 (en) | Shell-and-core dosage form approaching zero-order drug release | |
| EP1790334A2 (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
| KR100545480B1 (en) | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs | |
| MXPA99011232A (en) | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180605 |